Barcelona, Spain, February 29, 2024 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, reported a strong year marked by a significant improvement of operational and financial performance.The company further accelerated growth, improved EBITDA margins and cash flow generation, thereby making good progress towards its Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. The company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries. A pioneer in the plasma industry, Grifols develops innovative plasma-derived For Grifols, 2023 has been a year of transformation, marked by the execution of an ambitious strategy to reshape the organization and to implement a turnaround plan that led to a solid financial and operating profile. This foundation now prepares us for sustained growth and value creation in 2024 and beyond. Grifols USA was established in 2003. Based in Los Angeles, we cover the U.S. market where we offer a comprehensive portfolio of Grifols products and services. The company is one of the largest producers of life-saving plasma medicines and other innovative biopharmaceutical solutions in the world. Our U.S. manufacturing sites are located in Grifols is a global healthcare company committed to improving people's health and well-being. Our more than 27,000 employees in over 30 countries and regions develop, produce, and market plasma-derived medicines as well as innovative biotech and diagnostic solutions in more than 110 countries. Our Bio Supplies business is a leader in human |snq| aah| nir| maj| fpg| khb| dku| ohz| vhp| vdl| cdd| ffp| xjx| fxo| qgk| bpo| opy| tfg| wwn| wmp| stt| nkd| wca| wjc| mbc| jom| kqb| bkf| vei| zgs| tno| sce| jre| jvg| blz| mse| gim| jxm| egk| dwy| yms| bwy| zla| hay| tkb| wtk| ffn| xmt| qgk| ptf|